It is made available under a CC-BY 4.0 International license. perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2024.08.22.24312404;](https://doi.org/10.1101/2024.08.22.24312404) this version posted August 22, 2024. The copyright holder for this
preprint <mark>(which was not certified by peer review)</mark> is the author/funder, who has grant

It is made available under a CC-BY 4.0 International license.

Abstract 25

indicative of severe dengue. Out of 67 samples with adequate volume, 44 (65.6%) were positive for DENV 38 RNA using RT-PCR, and 21 successfully underwent CprM sequencing. All of them belonged to DENV-3, 39 genotype III, major lineage B (DENV-3III B), but represented two different minor lineages (DENV-3III_B.2 40 and DENV-3III B.3). Phylogenetic analysis demonstrated that both lineages were closely related to sequences 41 from the Afar region of Ethiopia collected in 2023, indicating that the outbreaks were related and were due to 42 multiple co-circulating lineages. 43 **Conclusions:** DENV-3III **B** was identified as the cause of the 2023 DF outbreak in Dire Dawa City. The 44

identification of two co-circulating lineages in this outbreak underscores the complex nature of DENV 45 transmission in the African continent and highlights the need for increased viral genomic surveillance.

Keywords: DENV, DF, Serotype, Genotype, CprM, DENV-3/GIII, Dire Dawa City, Ethiopia 47

48

24

- 49
- 50
- 51
	- 52
		-
		- 53
		-
		- 54
		- 55
	- 56

1. Introduction 57

Dengue fever (DF), caused by four genetically distinct serotypes of dengue virus (DENV-1 to DENV-4), 58 has become a significant global health challenge. Over the past two decades, the incidence of dengue has 59 increased tenfold, rising from 500,000 reported cases worldwide in 2000 to a staggering 5.2 million cases in 60 2019. In 2019, dengue outbreaks spread across 129 countries, marking an unprecedented peak. Although there 61 was a slight decline in cases between 2020 and 2022 due to the COVID-19 pandemic and reduced reporting 62 rates, 2023 witnessed a resurgence in dengue cases globally[1],[2],[3]. 63

In areas where DF cases have been identified as endemic and/or epidemic, especially in tropical and 64 subtropical countries, nonspecific febrile illnesses are common. Febrile illnesses can be caused by a variety 65 of infectious agents such as malaria parasites, alphaviruses, and flaviviruses, complicating surveillance and 66 response programs for outbreaks and endemic diseases[4]. In addition, the *Aede*s mosquito species, 67 particularly *Ae. Aegypti* and *Ae. Albopictus* that transmit DENV, are also responsible for the transmission of 68 other arboviruses (e.g., Zika virus, Yellow Fever virus, and Chikungunya virus), and are common in tropical 69 and subtropical countries[5]. 70

In Ethiopia, the first laboratory-confirmed outbreak of DF occurred in Deri Dawa City in 2013. Since 71 then, Ethiopia has experienced nearly annual outbreaks of DF in multiple regions of the country (Figure 1). 72 In the Afar Region, DF outbreaks occurred in 2019 in Gewane District [6]. In the Ethiopian Somalia region, 73 the first outbreak was reported in Godey town between 2014 and 2015 followed by outbreaks that occurred in 74 Kabridahar in 2017**[7]** and Warder Woreda in 2021**[8]**. These recurrent outbreaks have impacted an already 75 fragmented health system^[9] and the economy of these parts of the country. 76

In April 2023, an outbreak of DF was initially reported in the Afar region, the northeastern part of 77 Ethiopia. The first affected districts were Logia and Mille. Since April 4, 2023, however, it spread to all seven 78 districts and towns in the Afar region $(Figure 1)$. As of June 26, 2023, a total of 6,133 suspected and confirmed 79 cases were reported, resulting in nine associated deaths (with a case: fatality ratio of 0.5%)[10]. It was 80

documented that 8 of the 10 epidemic samples examined by RT-PCT triplex [for Dengue, Zika, and 81 Chikungunya] belonged to serotype DENV-3 [10]. 82

As a suspected expansion of the outbreak in the Afar region, a DF outbreak was recorded in Dire Dawa 83 City in December 2023 (Figure 1). However, there is no data regarding the DENV serotypes and genotypes 84 associated with the outbreak. Whether the outbreak was caused by DENV-3 as in the Afar region remains 85 unknown. In the present study, we present data on the serotypes, genotypes, and lineages of DENV strains 86 responsible for the outbreak in Dire Dawa City during 2023 and discuss the epidemiological and clinical 87 consequences. 88

2.1. Ethical considerations 90

2.1. Ethical considerations 91

As our study aimed to better understand DENV strains linked to DF outbreaks, we obtained an ethical approval 92 waiver (protocol number: PO-036-24) from the All-African Leprosy Rehabilitation and Training 93 Center/Armauer Hansen Research (ALERT/AHRI) Ethics Committee. [Additionally, we obtained](https://quillbot.com/paraphrasing-tool) permission 94 [from the Dire Dawa City Health Bureau and health facilities' authorities to investigate these outbreak](https://quillbot.com/paraphrasing-tool) 95 [samples.](https://quillbot.com/paraphrasing-tool) Since the samples used in this study were obtained from the dengue outbreak during the 2023 96 outbreak investigation and confirmation undertaken to respond to and control the public health emergencies, 97 no informed consent was obtained during the sample collection.

2.2. Study Settings and Patient Data 99

On December 14, 2023, the Ethiopia Public Health Institute (EPH) received 70 serum samples from an 100 outbreak of DF in Dire Dawa City Administration (Figure 1). These samples were collected from DF suspected 101 cases and shipped to the National Arbovirus Laboratory of EPHI for laboratory confirmation of the causative 102 agent as part of an outbreak response investigation (Figure 2). The reported clinical signs and symptoms for 103

each suspected case were extracted from medical charts available at the health facilities they were admitted 104 using a case-based surveillance request form. Mild symptoms include sudden onset of high fever, vomiting, 105 nausea, rash, arthralgia (joint pain), headache, chills, myalgia (muscle pain), sore throat, dizziness, runny nose, 106 pruritus (itchiness), adenosis, diarrhea and shivering while warning signs or indicative of severe dengue 107 include: belly pain or tenderness, persistent vomiting (at least 3 times/24 hrs), bleeding from the nose or gum, 108 restless or irritable, feeling weak, conjunctiva congestion and convulsions (Supplementary Table 1 and Table 109 2). The category of mild symptoms and warning signs indicative of severe dengue is based on the WHO severe 110 dengue classification [11]. 111

Each of the 70 dengue-suspected patients submitted blood samples for laboratory diagnosis of the 118 causative agent for febrile illness (Supplementary Table 1). The blood samples were allowed to clot, and the 119 sera were separated. The sera were then shipped in a triple package cold chain to the National Arbovirus 120 Laboratory of the EPHI. At the laboratory, the sera were kept frozen at −20°C until they were used for DENV 121 viremia detection using reverse transcriptase (RT)- PCR (RT-PCR). 122

2.4 Viral RNA Extraction and PCR Detection of DENV 123

Total RNA was isolated from each serum sample using the QIAmp viral RNA kit (QIAGEN, INC, 124 Valencia, CA). The RNA was eluted in 50 μl of AVE buffer, which was provided with the kit. DENV Viremia 125 Detection was done using RealStar® Dengue RT-PCR kit (Altona Diagnostics, Hamburg-Altona, Germany). 126 Briefly, 20 µ of the master mix (containing primers and probes) was mixed with 10 µ of the RNA sample or 127 control. The mixture was centrifuged for 30 seconds at approximately 1000 x g (~3000 rpm). The reactions 128 were incubated for 20 minutes at 55 °C, followed by 40 cycles of 95 °C for 1 min, 55 °C for 45 seconds, 72 °C 129 for 15 seconds, and final incubation at 68°C for 10 min. The PCR results were interpreted based on the 130 manufacturer's protocol. A threshold cycle (Ct) value of \leq 36 for DENV-specific RNA and a Ct value of \leq 30 131 for the Internal Control were considered positive samples for DENV. 132

2.5 Semi-Nested RT-PCR Amplification (Amplicon size 511 bp) 133

RNA samples with a Ct-value of 31 or lower and sufficient volume were selected for CprM RT-PCR 134 amplification following the procedure described elsewhere **[12]**. Briefly, the DENV CprM region (652) bp 135 was first amplified using forward primer (FP): 5′-TCAATATGCTGAAACGCGCGAGAAACCG-3′ (132– 136 153) and the reverse primer (RP): 5′- GCGCCTTCNGNNGACATCCA -3′ (764–783) and the high-capacity 137 cDNA reverse transcription kit (Invitrogen). The reactions were incubated first at 98°C for 10 seconds 138

followed by 35 cycles of 98°C for 10 seconds, 60°C for 20 seconds, 72°C for 30 seconds, and final incubation 139 at 72 °C for 5 minutes. Semi–nested PCR was also used to amplify 511 bp of the CprM region of the viral 140 genome using amplified product as a template, and the same FP: 5′- 141 TCAATATGCTGAAACGCGCGAGAAACCG-3′ (132–153) but a different RP-: 5'- 142 TTGCACCAACAGTCAATGTCTTCAGGTTC-3' (614-642)**[12]**. The semi-nested amplification was 143 performed in an Applied Biosystems Veriti 96-Well Thermal Cycler (ThermoFisher Scientific) using the 144 following cycling parameters: 94°C for 2 min; 40 cycles of 94°C for 30 s, 70°C for 1 s (ramp rate 20%), 55°C 145 for 45 s (ramp rate 20%), and 65° C for 3 min, 20 s; and final extension for 10 min at 65° C [13]. Following 146 the amplification, 5 μl of the first amplicon and semi-nested amplicon size of 652 bp and 511 bp, respectively 147 were visualized on ethidium bromide-stained agarose gel under UV light. Only the 511 bp DENV amplified 148 PCR products were purified using a QIAquick PCR purification Kit (QIAgen, Germany) and were sequenced 149 in both strands using a Big Dye Terminator Cycle Sequencing kit (Applied Biosystems), and the same primers 150 used for nested-PCR. The CprM sequences were confirmed by BLAST. The forward and reverse sequences 151 were aligned and manually edited using Bio Edit software to obtain the consensus sequence. The obtained 152 sequences were analyzed using **Dengue Virus Typing Tool at Genome Detective server** [13] to identify the 153 serotypes, genotypes, and lineages of DENV associated with the outbreak. 154

2.6 Phylogenetic analysis 155

3. Results 168

3.1. Patient characteristics 169

Among the 70 suspected dengue fever (DF) patients, 38 (54%) were female, as indicated in Table 1 and 170 Table S1. The median age was 30 with an interquartile (IQ) range of 17 years. Most (81%) of the suspected 171 cases visited health facilities as outpatients (Table 1 and Supplementary Table 1), while the remaining 13 172 cases required inpatient hospitalization for a duration of 2 to 10 days (Supplementary Table 1). 173

Table 1. Status of admission and demographic characteristics of dengue fever suspected cases (n = 174 70) reported at health facilities in the Dire Dawa City Administration, 2023. 175

176

167

The clinical signs/symptoms observed in these $(n = 70)$ DF suspected cases, whether admitted as 177 outpatients or inpatients, covered a wide range of symptoms consistent with febrile illness. Nearly all of them 178 exhibited three or more clinical symptoms consistent with mild DF (Supplementary Table 1). However, 179 regardless of hospitalization status, 32 (45.7%) of these patients displayed one or more early warning signs 180

indicative of severe dengue^[11]. Among the 13 patients who were hospitalized for 2 to 10 days, all except two 181 had at least one symptom indicative of severe dengue (Supplementary Table 1). The most commonly observed 182 clinical presentations were acute fever $(n = 66; 98.15\%)$, headache $(n = 65; 97.01\%)$ and chills $(n = 47; 183.01\%)$ 70.17%)) followed by aches and pains ($n = 31$; 46.27%) and vomiting/nausea ($n = 31$; 46.27%) (Table 2). In 184 addition, all of the cases with early warning signs of severe dengue were later confirmed to harbor DENV 185 viremia by RT-PCR. Supplementary Table 1 summarizes the details of the demographic and clinical 186 characteristics of study participants. 187

Table 2. Clinical characteristics of dengue fever suspected cases $(n = 70)$ reported at health facilities 188 in the Dire Dawa City Administration, 2023. 189

Clinical symptoms ¹	Yes ²	N ₀
A. Mild symptoms		
Fever: sudden onset of high fever	66(98.15%)	1(1.49%)
Chills	47(70.17%)	20(29.85%)
Vomiting or Nausea	31(46.27%)	36(53.73%)
Aches and Pains: Typically, behind the eyes, 31(46.27%)		36(53.73%)
muscle, joint, or bone pain		
Myalgia	28(45.9%)	33(54.1%)
Running nose	21(31.34%)	$46(68.66\%)$
Diarrhoea	13(19.4%)	54(89.60%)
Rash	$8(13.11\%)$	53(86.89%)
Sore throat	6(8.89%)	$61(91.04\%)$
Dizzy	5(7.46%)	62(92.54%)
Shivering	4(5.97%)	63(94.03%)
Pruritus	$2(2.99\%)$	65(97.01%)

It is made available under a CC-BY 4.0 International license.

Among the 67 samples that passed quality control, 65.67% (44/67) had DENV RNA detected(Figure 2). 195

It is made available under a CC-BY 4.0 International license. perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2024.08.22.24312404;](https://doi.org/10.1101/2024.08.22.24312404) this version posted August 22, 2024. The copyright holder for this
preprint <mark>(which was not certified by peer review)</mark> is the author/funder, who has grant

4. Discussion 235

Knowledge of the **genetic diversity** of DENV strains responsible for outbreaks is essential for efficient 236 management, vaccine development, and outbreak prevention. Though Ethiopia's eastern region, including 237 Dire Dawa City, has seen many DF outbreaks since 2013, there is scanty information regarding the genetic 238 diversity of circulating DENV strains. In this study, we used genetic analysis of the DENV CprM region to 239 demonstrate that the 2023 outbreak in Dire Dawa City was due to two co-circulating lineages of DENV- 240 3III B, each of which was closely related to sequences from a related outbreak in the Afar region of Ethiopia 241 in 2023. Our results are consistent with a recent study that analyzed 7 full DENV-3III genome sequences from 242 the Afar outbreak and found evidence for multiple introductions. However, the paucity of regional DENV 243 sequence data makes it difficult to determine the timing and origin of these introductions. Recently, other 244 DENV-3III outbreaks have been reported in East Africa, notably in South Sudan in 2022[18] and in Kenya in 245 2019[19]. We were not able to assess the genetic relatedness between the current strains and outbreak strains 246 from these neighboring countries due to the fact they employed other targets for sequencing such as the E_{1} 247 gene. These results underscore the need for further genomic surveillance of DENV in East Africa, ideally 248 using full-length genome sequences. 249

In contrast to the prior dengue outbreaks in Ethiopia which were more mild[7],[20],[21],[22], in this study 250 46% ($n = 32$) of the 70 DF-suspected cases displayed early warning signs indicative of severe dengue, while 251 the remaining cases showed mild symptoms. All of these cases with early warning signs of severe dengue 252 were confirmed to harbor DENV viremia by RT-PCR. 253

We propose three scenarios that might have led to the occurrence of severe cases of DF during the 2023 254 outbreak in Dire Dawa City. One possibility is the observed severe dengue cases could be secondary DENV- 255 3III infections that happened after primary infection with a different serotype. In support of this, prior DF 256 outbreaks reported from Dire Dawa City were associated with DENV-1 and DEV-2 strains 257 [7],[20],[21],[22],(Mesfin et al, in Press Viruses, MDPI), although previous attempts to determine serotypes 258

were restricted to a small number of DENV strains. Thus, the recurrent occurrence of dengue outbreaks 259 associated with different DENV serotypes calls for the need for close monitoring and management of future 260 DF outbreaks to effectively control and manage secondary infections. 261

The second possibility is that DENV-3III is more pathogenic, as suggested by prior research that 262 connected outbreaks of DENV-3III to Dengue Hemorrhagic Fever (DHF) and Dengue Shock Syndrome (DSS) 263 [23]. 264

The third possibility is that the severe cases may be the result of co-infection with malaria parasites, as 265 both infections are co-endemic in Dire Dawa City, and there is a chance that co-infection can worsen disease 266 severity and outcomes. This is supported by the recent surge in malaria[24],[25] and dengue cases[26],[27] in 267 Dire Dawa City which posed significant challenges for healthcare providers. Given the co-endemicity and 268 overlapping of symptoms (e.g., fever), there is a risk of co-infection with both dengue and malaria and 269 misdiagnosing dengue as malaria (and vice versa). Thus, an integrated approach involving surveillance, 270 education, and differential diagnosis is crucial for better patient care in Dire Dawa City Administration. 271 Healthcare professionals need to be aware of the clinical features, diagnostic tests, and management protocols 272 for malaria and dengue. In addition, the Dire Dawa City Administration should avail appropriate laboratory 273 tests (such as rapid diagnostic tests and PCR) at all health facilities that facilitate accurate diagnosis of dengue 274 and malaria and prompt treatment and management of severe cases. 275

Among the five distinct genotypes (I–V) of DENV-3, all 21 sequenced DENV strains from the present 276 study belonged to DENV-3III, which is the most widespread and was associated with large outbreaks in Asia, 277 Africa, and the Americas[28],[29],[30]. The first autochthonous case of DENV-3III in Africa was reported in 278 Mozambique in 1985[31]. Several man-made and natural factors, including (i) migration and conflict-related 279 population displacement, (ii) frequent migration via trade routes that can spread the virus to new areas, and 280 (iii) recurrent flooding that is made worse by climate change that provides ideal breeding grounds for Aedes 281 mosquitoes may have contributed to the rapid geographic expansion of DENV-3III in Africa, resulting in 282 outbreaks in areas like Dire Dawa City[3],[28],[32],[23],[33]. 283

Even though this work offers important insights into DENV strains responsible for the 2023 DF outbreak 284 in Dire Dawa City where severe cases and deaths were recorded, it suffers limitations. First, the study's 285 capacity to detect genetic variation was limited due to the use of a short genomic target (CprM, 511 base pairs) 286 for the characterization of the outbreak strains. Expanding the genomic coverage could have enhanced our 287 understanding of DENV diversity and relationships to other DENV-3III strains across the globe. Second, 288 DENV CprM sequencing was performed on a small proportion of DF-suspected cases reported during the 289 outbreak, and a larger sample size may have identified greater genetic diversity. Third, the study lacks 290 information on other febrile illness-causing pathogens like malaria parasite examination with microscopy or 291 rapid diagnostic test results, for the studied DF-suspected cases, so cases of co-infection may have been 292 missed. Future research addressing these limitations will therefore improve our comprehension of disease 293 dynamics, provide a thorough understanding of DENV strains and their evolutionary history, expand our 294 understanding of DENV outbreaks, and provide guidance for more effective preventative measures. 295

5. Conclusions 296

In summary, our results demonstrate that the 2023 DF outbreak in Dire Dawa City, Ethiopia, was due to 297 multiple co-circulating lineages of DENV-3III. The severe cases recorded during this outbreak may be due to 298 either the genetic makeup of DENV-3III, secondary DENV infection, or co-infection of DENV and malaria. 299 Additionally, the intercontinental transmission of DENV-3III underscores the importance of vigilant 300 surveillance and preparedness to mitigate the impact of such outbreaks. Thus, collaborative efforts across 301 borders are crucial for effective prevention and control strategies. 302

Supplementary Materials: Supplementary Table 1: Demographic and clinical parameters of dengue 303 suspected patients and Supplementary Table 2: Laboratory investigation of dengue confirmed patients, 304 including DENV serotype and genotype with their corresponding GenBank Accession Numbers. 305

Author Contributions: Conceptualization, A.A.N. and S.A.A.; study design, S.A.A., A.Mu. And T.G.; 306 methodology, A. Mu., S.A.A., T.G., H.A.; software, T.G.; validation, T.G., **DM.RG.**, A.A.N., and Z.Z.; formal 307 analysis, T.G., **DM.RG.**, and A.Ay.; Laboratory investigations, D.H.A., T.K.W., G.B., A.H.B, D.T., E.A, 308

EZA, A.As, A.K.K., K.M., and R.J.; resources, A.Mu, A.Mi., S.A.A., A.Ab., G.T., M.H; Field data and 309 samples acquisition, E.Z.A., D.T., and A.K.K. data curation, T.G., and A.A.N.; writing—original draft 310 preparation, T.G., and A.A.N.; writing—review and editing, T.G., A.P., A.Mu., and A.A.N.; visualization, 311 T.G., **DM.RG,** A.Ay., and A.P.; supervision, S.A.A. All authors have read and agreed to the published version 312 of the manuscript. 313

Funding: This research received no external funding. 314

Acknowledgments 315

We would like to thank all study participants in this study. We are also grateful for the support and cooperation 316 we received from physicians, nurses of Dire Dawa City health facilities, and administrative authorities of Dire 317 Dawa City Administration Health Hureau and the health facilities administration. The authors acknowledge 318 EPHI's support of the field study and AHRI and EPHI's reagent support of the molecular analysis. 319

Conflicts of Interest 321

The authors declare no conflicts of interest. 322

Data Availability Statement 323

The datasets generated and/or analyzed during the current study are available in the manuscript and the 324 Supplementary Materials. The sequence data presented in this study are openly available in the GenBank 325 database, accession numbers PP751832-PP751852.

327

320

References 328

1. Dengue- Global situation. https://www.who.int/emergencies/disease-outbreak-news/item/2023-DON498. 329 Accessed 7 Apr 2024. 330

2. Yang X, Quam MBM, Zhang T, Sang S. Global burden for dengue and the evolving pattern in the past 331 30 years. Journal of Travel Medicine. 2021;28:taab146. 332 3. Geographical expansion of cases of dengue and chikungunya beyond the historical areas of transmission in 333 the Region of the Americas. https://www.who.int/emergencies/disease-outbreak-news/item/2023-DON448. 334 Accessed 7 Apr 2024. 335

4. Roy SK, Bhattacharjee S. Dengue virus: epidemiology, biology, and disease aetiology. Can J Microbiol. 336 2021;67:687–702. 337

5. Dengue and severe dengue. https://www.who.int/news-room/fact-sheets/detail/dengue-and-severe-dengue. 338 Accessed 25 Feb 2024. 339

6. Mekuriaw W, Kinde S, Kindu B, Mulualem Y, Hailu G, Gebresilassie A, et al. Epidemiological, 340 Entomological, and Climatological Investigation of the 2019 Dengue Fever Outbreak in Gewane District, Afar 341 Region, North-East Ethiopia. Insects. 2022;13:1066. 342

7. Gutu MA, Bekele A, Seid Y, Mohammed Y, Gemechu F, Woyessa AB, et al. Another dengue fever outbreak 343 in Eastern Ethiopia—An emerging public health threat. PLOS Neglected Tropical Diseases. 344 2021;15:e0008992. 345

8. Mesfin Z, Ali A, Abagero A, Asefa Z. Dengue Fever Outbreak Investigation in Werder Town, Dollo Zone, 346 Somali Region, Ethiopia. Infection and Drug Resistance. 2022;15:7207–17. 347

9. Mohan A, Fakhor H, Nimavat N, Wara UU, Lal PM, Costa AC dos S, et al. Dengue and COVID-19: A risk 348 of coepidemic in Ethiopia. J Med Virol. 2021;93:5680–1. 349

10. Sisay C, Tadesse A, Workie F, Yizengaw A, Ali A, Yusuf J, et al. Description of Serotype 3 Dengue Fever 350 Virus: Clinical, Surveillance and Geographical Expansion in the Northeastern Ethiopia. Science Journal of 351 Public Health. 2023. https://doi.org/10.11648/j.sjph.20231104.12. 352

11. Htun TP, Xiong Z, Pang J. Clinical signs and symptoms associated with WHO severe dengue 353 classification: a systematic review and meta-analysis. Emerg Microbes Infect. 10:1116–28. 354

12. Lanciotti RS, Calisher CH, Gubler DJ, Chang GJ, Vorndam AV. Rapid detection and typing of dengue 355 viruses from clinical samples by using reverse transcriptase-polymerase chain reaction. Journal of Clinical 356 Microbiology. 1992;30:545–51. 357

13. Hill V, Cleemput S, Fonseca V, Tegally H, Brito AF, Gifford R, et al. A new lineage nomenclature to aid 358 genomic surveillance of dengue virus. 2024;:2024.05.16.24307504. 359

14. Katoh K, Standley DM. MAFFT Multiple Sequence Alignment Software Version 7: Improvements in 360 Performance and Usability. Mol Biol Evol. 2013;30:772–80. 361

15. Nguyen L-T, Schmidt HA, von Haeseler A, Minh BQ. IQ-TREE: A Fast and Effective Stochastic 362 Algorithm for Estimating Maximum-Likelihood Phylogenies. Molecular Biology and Evolution. 363 2015;32:268–74. 364

16. Letunic I, Bork P. Interactive Tree Of Life (iTOL) v5: an online tool for phylogenetic tree display and 365 annotation. Nucleic Acids Research. 2021;49:W293–6. 366

17. Mekonnen F, Khan BA, Nibret E, Munshea A, Tsega D, Endalamaw D, et al. Introduction of Dengue 367 Virus Serotype 3 in the Afar Region, Ethiopia. 2024;:2024.07.19.24310689. 368

18. Eldigail MH, Abubaker HA, Khalid FA, Abdallah TM, Musa HH, Ahmed ME, et al. Association of 369 genotype III of dengue virus serotype 3 with disease outbreak in Eastern Sudan, 2019. Virology Journal. 370 2020;17:118. 371

19. Muthanje EM, Kimita G, Nyataya J, Njue W, Mulili C, Mugweru J, et al. March 2019 dengue fever 372 outbreak at the Kenyan south coast involving dengue virus serotype 3, genotypes III and V. PLOS Glob Public 373 Health. 2022;2:e0000122. 374

20. Biru M, Geleta D. Dengue Fever Outbreak Investigation and Response in Dire Dawa City Administration, 375 Ethiopia, 2017. Journal of Medicine. 2020. 376

21. Zerfu B, Kassa T, Legesse M. Epidemiology, biology, pathogenesis, clinical manifestations, and diagnosis 377 of dengue virus infection, and its trend in Ethiopia: a comprehensive literature review. Tropical Medicine and 378 Health. 2023;51:11. 379

22. Sisay C, Waldetensai A, Seyoum M, Tayachew A, Wossen M, Keneni D, et al. Detection of serotype 1- 380 Dengue fever outbreak in Dire Dawa city, Eastern Ethiopia. Ethiopian Journal of Public Health and Nutrition 381 (EJPHN). 2022;5:49–54. 382

23. Messer WB, Gubler DJ, Harris E, Sivananthan K, Silva AM de. Emergence and Global Spread of a Dengue 383 Serotype 3, Subtype III Virus - Volume 9, Number 7—July 2003 - Emerging Infectious Diseases journal - 384 CDC. https://doi.org/10.3201/eid0907.030038. 385

24. A malaria outbreak in Ethiopia came from an invasive Asian mosquito. 2022. 386 https://www.sciencenews.org/article/malaria-outbreak-ethiopia-invasive-mosquito-asia. Accessed 11 Mar 387 2024. 388

25. Emiru T, Getachew D, Murphy M, Sedda L, Ejigu LA, Bulto MG, et al. Evidence for a role of Anopheles 389 stephensi in the spread of drug- and diagnosis-resistant malaria in Africa. Nat Med. 2023;29:3203–11. 390

26. Degife LH, Worku Y, Belay D, Bekele A, Hailemariam Z. Factors associated with dengue fever outbreak 391 in Dire Dawa administration city, October, 2015, Ethiopia - case control study. BMC Public Health. 392 2019;19:650. 393

27. Nigussie E, Atlaw D, Negash G, Gezahegn H, Baressa G, Tasew A, et al. A dengue virus infection in 394 Ethiopia: a systematic review and meta-analysis. BMC Infectious Diseases. 2024;24:297. 395

28. Maquart M. Circulation of Dengue Virus Type 3 Genotype III in Africa Since 2008. JHVRV. 2016;4. 396

It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) . perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2024.08.22.24312404;](https://doi.org/10.1101/2024.08.22.24312404) this version posted August 22, 2024. The copyright holder for this
preprint <mark>(which was not certified by peer review)</mark> is the author/funder, who has grant

Figure 1

Febrile illness suspected and confirmed dengue cases visiting health facilities of Dire Dawa City Administration ($n = 1,638$), December 2023 with nine deaths (a case fatality ratio of 0.5%)

Figure 2

